Potential of CLSPN as a therapeutic target in melanoma: a key player in melanoma progression and tumor microenvironment
These findings suggest that CLSPN may be a promising new target for melanoma and accelerate personalized therapeutic strategies.
Authors
- Yeqiang Liu (ORCID: https://orcid.org/0000-0003-3758-1390)
- Yongyi Xie (ORCID: https://orcid.org/0000-0001-7750-2373)
- Jiashe Chen
- Xiaoxiang Xu (ORCID: https://orcid.org/0000-0002-1043-0640)
- Nanhui Wu (ORCID: https://orcid.org/0000-0002-2006-2220)
- Mingyuan Xu (ORCID: https://orcid.org/0000-0003-1728-0769)
- Yunfeng Bai (ORCID: https://orcid.org/0000-0003-1675-0570)
- Xin Ma (ORCID: https://orcid.org/0000-0002-6051-1924)
- Wei Hong Tan (ORCID: https://orcid.org/0000-0001-6008-3854)
- Yanbin Chen (ORCID: https://orcid.org/0000-0001-8678-5934)
- Fei Wu (ORCID: https://orcid.org/0000-0002-9100-4335)
- Ruoqi Wang (ORCID: https://orcid.org/0009-0005-6989-1926)
Institutions
- Tongji University (CN)
- Baosteel (China) (CN)
- Shanghai Skin Disease Hospital (CN)
- Tongji Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1186/s12967-025-06455-w
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shanghai